Spanning 18 Level 1 Trauma Centers across the country, TRACK-TBI NET is paving the way toward a new generation of precision medicine traumatic brain injury clinical trials.

Using innovative trial design and imaging and blood-based biomarkers of brain injury to enrich study populations, TRACK-TBI NET aims to reverse the course of failed TBI clinical trials.
Using objective imaging and the FDA-cleared blood-based biomarkers, TRACK-TBI NET stratifies study subjects into cohorts according to the specific characteristics of their traumatic brain injury.
The TRACK-TBI NET Central Neuroimaging Repository is hosted at the computing facility at the California Institute for Quantitative Biosciences on the UCSF Mission Bay campus and overseen by information technology personnel of the UCSF Radiology Scientific Computing Services.
TRACK-TBI NET utilizes a central, state-of-the art biospecimen repository at University of Pittsburgh Medical Center. Blood and serum samples are collected, processed, and stored at -80°C at the local participating sites until shipped to the UPMC biorepository. Once samples are received, an uninterrupted electronic train of custody is maintained.

TRACK-TBI NET is a multi-faceted Phase 2 TBI clinical trial network that builds on the well-established infrastructure of its foundation: the longitudinal, observational TRACK-TBI study. This institutional and public-private partnership is comprised of 18 Clinical Enrollment/Study Sites, 7 Cores, and a Contract Research Organization, for a total of nearly 50 collaborating institutions, corporations, and philanthropic organizations. Following a decade of progress, the TRACK-TBI NETWORK  is strategically positioned to transition from an observational natural history study to a robust platform for TBI intervention trials. Funded in part by the United States Department of Defense US Army Medical Materiel Development Activity (DoD USAMMDA) via the Medical Technology Enterprise Consortium, TRACK-TBI NET invites all members of the TBI research community, across academic, public, and private platforms, to propose candidate pharmaceutical agents for Phase 2 studies.